ストックスクリーナーアプリを入手
23.45
1.16%
0.27
アフターアワーズ：
23.42
-0.03
-0.13%
前日終値:
$23.18
開ける：
$23.325
24時間の取引高:
26.07M
Relative Volume:
0.53
時価総額：
$133.32B
収益：
$62.46B
当期純損益:
$7.88B
株価収益率:
16.99
EPS:
1.38
ネットキャッシュフロー:
$11.22B
1週間 パフォーマンス:
+1.78%
1か月 パフォーマンス:
-1.43%
6か月 パフォーマンス:
-10.53%
1年 パフォーマンス:
-15.71%
1日の値動き範囲:
$23.16
$23.45
1週間の範囲:
$22.88
$23.66
52週間の値動き範囲:
$20.91
$31.54
Pfizer Inc Stock (PFE) Company Profile
PFE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
23.45 | 130.99B | 62.46B | 7.88B | 11.22B | 1.38 |
|
LLY
Lilly Eli Co
|
722.57 | 642.06B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
153.58 | 367.19B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
185.62 | 322.44B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
112.58 | 222.20B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
69.46 | 302.90B | 43.59B | 15.04B | 10.74B | 3.3766 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-25 | 再開されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | ダウングレード | Argus | Buy → Hold |
| 2024-02-23 | 開始されました | Guggenheim | Buy |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-10-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-17 | 繰り返されました | JP Morgan | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-06-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | ダウングレード | UBS | Buy → Neutral |
| 2023-01-17 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-13 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-20 | 繰り返されました | Cowen | Outperform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-13 | アップグレード | UBS | Neutral → Buy |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | アップグレード | DZ Bank | Hold → Buy |
| 2020-12-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 再開されました | Goldman | Neutral |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-10-12 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-16 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-27 | アップグレード | Standpoint Research | Hold → Buy |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-07-30 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 再開されました | Morgan Stanley | Overweight |
| 2019-02-20 | 再開されました | Citigroup | Neutral |
| 2019-01-31 | アップグレード | Argus | Hold → Buy |
| 2019-01-31 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | ダウングレード | UBS | Buy → Neutral |
| 2018-12-11 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-01 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
すべてを表示
Pfizer Inc (PFE) 最新ニュース
Pfizer Inc. (PFE) Ends Acepodia Partnership Amid Depo-Provera Legal Woes - Yahoo Finance
Pfizer (NYSE:PFE) Ends Collaboration With Acepodia And Faces Depo-Provera Legal Challenges - simplywall.st
Pfizer (PFE) Down 5% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Are Investors Undervaluing Pfizer (PFE) Right Now? - Nasdaq
Pfizer's Mega Deal Highlights China's Rising Role In Global Pharma - Benzinga
Berenberg Bank Cuts Pfizer Price Target to $25 From $28, Maintains Hold Rating - marketscreener.com
5 Rock-Solid Dividend Stocks Under $50 With Room to Run - 24/7 Wall St.
Old COVID tweet lands Pfizer in new trouble with PMCPA - pharmaphorum
PFIZER INC : Berenberg reaffirms its Neutral rating - marketscreener.com
Acute Myeloid Leukemia Market Detailed Analysis and Forecast - openPR.com
Pfizer (PFE) Stock Slides Over 2%, Hits Day’s Low in Afternoon Trading - Daily Chhattisgarh News
With 67% ownership of the shares, Pfizer Inc. (NYSE:PFE) is heavily dominated by institutional owners - Yahoo Finance
U.S. Vaccine Market Set to Witness Robust ExpansionPfizer, Moderna - openPR.com
Acepodia and Pfizer To Terminate Cooperation in Autoimmune Diseases Drugs Development - marketscreener.com
Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market? - The Motley Fool
FDA Warns of Heart Risk With Pfizer, Moderna COVID Vaccines - Endocrinology Advisor
Unlocking Pfizer's Value: Cost Controls And Oncology Pipeline - Seeking Alpha
US drops COVID vaccine recommendation for healthy kids, pregnant women - marketscreener.com
Mixed options sentiment in Pfizer with shares up 0.88% - TipRanks
US drops COVID vaccine recommendations for healthy children, pregnant women - marketscreener.com
Sleep Aids Market Generated Opportunities, Future Scope - openPR.com
Is Pfizer Stock a Buy After This $1.25 Billion Investment? - The Globe and Mail
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Enamine to Enable Access to Selected Pfizer Reference Compounds to Support the Global Research CommunityMETRO - METRO - NEWS CHANNEL NEBRASKA
Specialty Injectable Generics Market Is Booming So Rapidly - openPR.com
Immunostimulant Drugs Market Is Booming So Rapidly 2025-2032 - openPR.com
Chlorphenamine Maleate API Market Trends, Demand, and Future Outlook | Pfizer Inc., Novartis AG, Sanofi S.A. - openPR.com
Pfizer, Inc. (PFE) Stock Analysis: Evaluating a 26.50% Potential Upside Amidst Challenges - DirectorsTalk Interviews
Investing In The Promising PD1/VEGF Bispecific; Pfizer And Instil Could Be Good Candidates - Seeking Alpha
Pfizer (PFE) Secures $1.25B Cancer Drug Licensing Deal - GuruFocus
Was Jim Cramer Right About Pfizer Inc. (PFE)? - MSN
25,379 Shares in Pfizer Inc. (NYSE:PFE) Bought by PVG Asset Management Corp - InsuranceNewsNet
Pfizer’s SWOT analysis: stock outlook amid strategic moves and pipeline potential - Investing.com India
Pfizer Inc. (PFE) Delivers Oncology Milestones with MesoC2 Debut and XTANDI Survival Boost - Yahoo Finance
Down 63%, Should You Buy the Dip on Pfizer? - AOL.com
Pfizer's 7.5% Dividend: Income Haven or House of Cards? - MSN
Pfizer (NYSE:PFE) Showcases New Cancer Treatment Study And Reports Prostate Cancer Drug Success - simplywall.st
Type 2 Diabetes Market to Expand Significantly by 2034, States DelveInsight Report | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - The Globe and Mail
Pfizer Inks $1.25 Billion Deal with 3SBio for Global Rights to Cancer Drug - Contract Pharma
FDA Advisory Panel Backs COVID Vaccine Update, Impacting Pfizer (PFE) - GuruFocus
Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting - PR Newswire
Astellas and Pfizer's XTANDI Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer - Investing News Network
Fed. Circ. Backs Pfizer Win Against Gene Therapy Patents - Law360
Astellas and Pfizer’s XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer - Pfizer
Pfizer, Astellas Pharma's Prostate Cancer Treatment Shows 30% Reduction in Risk of Death - marketscreener.com
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Ove - GuruFocus
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer - Yahoo Finance
COVID shots should target newer strains of JN.1 variant, US FDA advisers say - marketscreener.com
The Mindfulness of Medicine Development: Advancing Treatments Can Transform Patient Outcomes - Pfizer
Pfizer Cements Win Axing Hemophilia Patents at Federal Circuit - Bloomberg Law News
Pfizer Inc (PFE) 財務データ
収益
当期純利益
現金流量
EPS
2.46%
大文字化:
|
ボリューム (24 時間):